{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/biib-stock-analysis/",
 "dataUrl": "https://clearank.com/stock/biib-stock-analysis/data.json",
 "title": "Biogen Inc. (BIIB) Stock Forecast & Price Target (2026)",
 "description": "Biogen Inc. (BIIB) stock: Healthcare, Drug Manufacturers - General. $32.1B market cap. AI rating, technicals, 2030 forecast and trade plans.",
 "headline": "Biogen Inc. (BIIB)",
 "published": "2026-08-20T06:31:53+00:00",
 "modified": "2026-09-11T22:03:17.589+00:00",
 "generated": "2026-09-12T23:14:08.254Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "BIIB",
  "name": "Biogen Inc.",
  "type": "Common Stock",
  "exchange": "NASDAQ",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Drug Manufacturers - General",
  "country": "United States",
  "website": "https://www.biogen.com"
 },
 "quote": {
  "price": 217.1,
  "previousClose": 215.43,
  "change": 1.67,
  "changePercent": 0.78,
  "open": 216.75,
  "high": 219.76,
  "low": 214.71249,
  "volume": 871507,
  "averageVolume": 753821,
  "marketCap": 32077394443,
  "fiftyTwoWeekHigh": 225.8,
  "fiftyTwoWeekLow": 131.52,
  "marketOpen": false,
  "asOf": "2026-09-11T22:03:16.000Z"
 },
 "statistics": {
  "pe": 37.466087,
  "eps": 5.75,
  "dividendYield": 0,
  "beta": 0.171,
  "priceToSales": 3.1742082,
  "priceToBook": 1.6881905,
  "revenueTtm": 10027899904,
  "grossMargin": 0.7160453216374268,
  "returnOnEquity": 0.04575
 },
 "technicals": {
  "rsi": 50.41,
  "macd": 2.02,
  "sma50": 209.47,
  "sma200": 191.92,
  "rsiSignal": "Neutral",
  "trend": "Bullish",
  "pricePosition": "Bullish",
  "macdSignal": "Bullish",
  "rating": "Bullish"
 },
 "analysis": {
  "rating": "Buy",
  "score": 68,
  "consensus": "Buy",
  "fairValue": 217.1,
  "analystTarget": 240,
  "analystCount": 35,
  "wallStreetConsensus": "Buy",
  "generatedAt": "2026-09-11T22:03:16.000Z",
  "priceAtAnalysis": 217.10001,
  "volatility": {
   "daily": 1.77,
   "risk": "standard"
  }
 },
 "tradePlan": {
  "bias": "Bullish",
  "conservativeEntry": 212.76,
  "aggressiveEntry": 217.1,
  "stopLoss": 205.25,
  "stopLossPercent": 3.53,
  "targets": [
   223.4,
   234.03,
   244.67
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 131.48,
    "base": 219.68,
    "upside90th": 367.04
   },
   {
    "year": 2028,
    "downside10th": 107.56,
    "base": 222.29,
    "upside90th": 459.39
   },
   {
    "year": 2029,
    "downside10th": 92.45,
    "base": 224.93,
    "upside90th": 547.21
   },
   {
    "year": 2030,
    "downside10th": 81.53,
    "base": 227.6,
    "upside90th": 635.36
   },
   {
    "year": 2031,
    "downside10th": 73.08,
    "base": 230.3,
    "upside90th": 725.72
   },
   {
    "year": 2032,
    "downside10th": 66.28,
    "base": 233.04,
    "upside90th": 819.36
   },
   {
    "year": 2033,
    "downside10th": 60.64,
    "base": 235.8,
    "upside90th": 916.96
   },
   {
    "year": 2034,
    "downside10th": 55.87,
    "base": 238.6,
    "upside90th": 1019.07
   },
   {
    "year": 2035,
    "downside10th": 51.76,
    "base": 241.44,
    "upside90th": 1126.1
   },
   {
    "year": 2036,
    "downside10th": 48.19,
    "base": 244.3,
    "upside90th": 1238.46
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "BIIB Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$216.75",
    "Day Range": "$214.71 to $219.76",
    "Prev Close": "$215.43",
    "Volume": "871.5K",
    "52-Week Range": "$131.52 to $225.80",
    "Market Cap": "$32.08B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis Valuation is broadly in line with sector peers (17% difference), suggesting fair market pricing relative to industry standards."
   ]
  },
  {
   "id": "financials",
   "title": "BIIB Financial Performance",
   "text": [
    "Analysis: In the last 5 quarters, BIIB beat estimates 4 times. However, the stock fell 3 times the next day. This suggests positive news is often \"priced in\" or investors are selling the news."
   ]
  },
  {
   "id": "analysis",
   "title": "BIIB Analysis",
   "text": [
    "Biogen Inc. is trading above its 50-day and 200-day moving averages ($209.47 and $191.92), at $209.47 and $191.92 respectively, indicating a bullish trend. The RSI is at 50.41, reflecting neutral momentum, and the MACD is at 2.02, suggesting a lack of strong directional conviction. The stock is also trading above its 20-day EMA of $215.66. Volume on the latest trading day was 871,507, which is 15.6% above the average volume of 753,821, suggesting increased investor interest. Key support levels are near the 50-day SMA, while resistance is implied by the median analyst target price of $240. The neutral RSI suggests the stock is neither overbought nor oversold, positioning it for potential continuation of its current trend.",
    "Biogen Inc. has a history of exceeding EPS estimates, most recently with a 77.34% surprise, indicating strong operational execution and profitability.",
    "The stock is trading above its 50-day and 200-day moving averages ($209.47 and $191.92), indicating a generally positive technical trend and potential for continued upward movement.",
    "Insiders have sold $1.8 million versus purchased $152.1 thousand, signaling a 'Moderate Sell Signal' and potentially indicating a lack of strong conviction from management.",
    "The Relative Strength Index (RSI) is at 50.41, indicating neutral momentum and suggesting the stock is neither overbought nor oversold, which could lead to range-bound trading.",
    "Biogen Inc. is expected to maintain its current trading range in the near term, with a base case scenario targeting the median analyst price of $240 within the next 6-12 months. The company's consistent earnings beats and its position above key moving averages provide a stable foundation for this outlook. Continued success in drug development and market penetration will be key to achieving higher valuations. Potential upside catalysts include positive clinical trial results for new therapies or strategic partnerships that expand its product pipeline. Conversely, a significant downside risk would be regulatory setbacks, increased competition from emerging biotech firms, or a shift in market sentiment away from healthcare stocks. The moderate insider selling also warrants attention as a potential indicator of future performance."
   ],
   "lists": {
    "ProTips": [
     "Monitor upcoming clinical trial results and regulatory approvals for key Biogen drugs, as these are significant catalysts for future growth.",
     "Given the neutral RSI, consider waiting for a clearer technical signal or a pullback to a support level before initiating new positions.",
     "The moderate insider selling suggests caution; investors should pay close attention to any further selling pressure or any significant insider buying that might reverse this trend."
    ]
   },
   "catalysts": [
    {
     "type": "Bullish",
     "title": "Consistent Earnings Beats",
     "text": "Biogen Inc. has a history of exceeding EPS estimates, most recently with a 77.34% surprise, indicating strong operational execution and profitability.",
     "source": "Earnings Reports"
    },
    {
     "type": "Bullish",
     "title": "Trading Above Key Moving Averages",
     "text": "The stock is trading above its 50-day and 200-day moving averages ($209.47 and $191.92), indicating a generally positive technical trend and potential for continued upward movement.",
     "source": "Technical Analysis"
    },
    {
     "type": "Bearish",
     "title": "Moderate Insider Selling",
     "text": "Insiders have sold $1.8 million versus purchased $152.1 thousand, signaling a 'Moderate Sell Signal' and potentially indicating a lack of strong conviction from management.",
     "source": "Insider Transactions"
    },
    {
     "type": "Neutral",
     "title": "Neutral RSI Momentum",
     "text": "The Relative Strength Index (RSI) is at 50.41, indicating neutral momentum and suggesting the stock is neither overbought nor oversold, which could lead to range-bound trading.",
     "source": "Technical Analysis"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "Biogen Inc. operates in the Drug Manufacturers - General industry, which has a median P/E ratio of 31.9. The company's current P/E ratio of 37.47, suggesting it trades at a slight premium to its sector peers. Revenue growth has been reported at 3.4%, with analyst estimates projecting a 4.00% increase for the current quarter and 6.00% for the full year. The company's ability to consistently beat EPS estimates, as seen in the recent earnings reports, indicates strong operational execution and profitability. The consistent earnings performance and positive revenue outlook suggest a stable financial footing. The current valuation appears reasonable given the company's consistent earnings beats and its position within the healthcare sector, though it trades slightly above the sector's median P/E.",
    "Biogen Inc. has a strong track record of exceeding analyst earnings per share (EPS) expectations, most recently reporting an EPS of $3.60 against an estimate of $2.03 for the quarter ending July 29, 2026, a significant 77.34% surprise. This beat, however, was followed by a 0.62% decrease in stock price. Prior quarters also show consistent positive surprises, with the exception of a slight miss in the March 2026 quarter. Revenue growth is projected to be around 4.00% for the current quarter.",
    "A primary risk for Biogen Inc. stems from insider selling, with $1.8 million in sales versus $152.1 thousand in purchases, indicating a moderate sell signal from management. While the stock is trading above key moving averages, the neutral RSI suggests a lack of strong upward momentum, potentially limiting near-term gains. Competition within the drug manufacturing sector remains a persistent challenge, requiring continuous innovation and successful clinical trial outcomes."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "32.08B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "37.47"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "5.75"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "0.00%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "225.80"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "131.52"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bullish RSI Neutral SMA Cross Bullish Price vs SMA Bullish MACD Bullish Golden Cross in effect with the 50-day SMA ($209.47) above the 200-day SMA ($191.92), price action is firmly bullish above key moving averages."
   ],
   "facts": {
    "RSI": "Neutral",
    "SMA Cross": "Bullish",
    "Price vs SMA": "Bullish",
    "MACD": "Bullish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "50.41"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "2.02"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "209.47"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "191.92"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.26",
    "Correlation with Nasdaq 100 (QQQ)": "+0.17",
    "Correlation with Bitcoin (BTC)": "-0.08",
    "Correlation with Gold (XAU)": "+0.02"
   }
  },
  {
   "id": "trade-plans",
   "title": "BIIB Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Lower risk, wait for pullback",
    "Higher risk, immediate entry",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (50.4) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$223.40",
    "TARGET 2": "$234.03",
    "TARGET 3": "$244.67",
    "STOP LOSS": "$205.25"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "+0.49%",
    "Average Feb return": "-2.59%",
    "Average Mar return": "-4.63%",
    "Average Apr return": "+0.06%",
    "Average May return": "+0.39%",
    "Average Jun return": "+3.35%",
    "Average Jul return": "+0.16%",
    "Average Aug return": "+0.34%",
    "Average Sep return": "+1.87%",
    "Average Oct return": "-1.91%",
    "Average Nov return": "+1.46%",
    "Average Dec return": "-1.29%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "1.77%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in BIIB in September 2016 would be worth about $7,118 today, compared with about $35,030 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in BIIB today could grow to about $11,253 by 2036 in the base case, with a bull case near $57,045 and a bear case around $2,220. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "BIIB Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $228 for BIIB by 2030 in the base case, from $217 today (1.0x over 4 years). The downside path ends near $81.53. These are outcomes of a Monte Carlo simulation run on BIIB's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using BIIB's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "BIIB simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$131",
        "$220",
        "$367"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$108",
        "$222",
        "$459"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$92.45",
        "$225",
        "$547"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$81.53",
        "$228",
        "$635"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$73.08",
        "$230",
        "$726"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$66.28",
        "$233",
        "$819"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$60.64",
        "$236",
        "$917"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$55.87",
        "$239",
        "$1,019"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$51.76",
        "$241",
        "$1,126"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$48.19",
        "$244",
        "$1,238"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "NEOG Neogen Corp. NASDAQ $11.78 +0.08%",
     "url": "https://clearank.com/stock/neogen-neog/"
    },
    {
     "text": "MOH Molina Healthcare Inc. NYSE $204.23 +1.97%",
     "url": "https://clearank.com/stock/moh-stock-analysis/"
    },
    {
     "text": "VKTX Viking Therapeutics, Inc. NASDAQ $31.98 -0.47%",
     "url": "https://clearank.com/stock/viking-therapeutics-vktx/"
    },
    {
     "text": "BMY Bristol-Myers Squibb Company NYSE $63.64 -0.17%",
     "url": "https://clearank.com/stock/bristol-myers-squibb-bmy/"
    },
    {
     "text": "VEEV Veeva Systems Inc. NYSE $262.25 +0.49%",
     "url": "https://clearank.com/stock/veev-stock-analysis/"
    },
    {
     "text": "TLRY Tilray Brands Inc. NASDAQ $4.02 -2.90%",
     "url": "https://clearank.com/stock/tilray-brands-tlry/"
    },
    {
     "text": "CRNX Crinetics Pharmaceuticals, Inc. NASDAQ $84.95 +0.00%",
     "url": "https://clearank.com/stock/crinetics-pharmaceuticals-crnx/"
    },
    {
     "text": "CNC Centene Corp. NYSE $66.42 +1.56%",
     "url": "https://clearank.com/stock/centene-cnc/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Popular Comparisons",
   "links": [
    {
     "text": "SLV vs SIVR Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/slv-vs-sivr/"
    },
    {
     "text": "TSLA vs NVDA Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/tsla-vs-nvda/"
    },
    {
     "text": "VGT vs QQQM Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/vgt-vs-qqqm/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "BIIB Insider Trading Analysis",
   "facts": {
    "Bought": "$152.1K",
    "Sold": "$1.8M",
    "Insiders": "20",
    "Avg Transaction": "$238.4K"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in BIIB",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Jun 7, 2021",
       "cells": [
        "SANDROCK ALFRED W JR Officer",
        "Sell",
        "7.7K",
        "$3.4M"
       ]
      },
      {
       "label": "Jul 19, 2017",
       "cells": [
        "ALEXANDER SUSAN H Officer",
        "Sell",
        "7.8K",
        "$2.2M"
       ]
      },
      {
       "label": "Mar 18, 2019",
       "cells": [
        "PANGIA ROBERT W Director",
        "Sell",
        "6.1K",
        "$2.0M"
       ]
      },
      {
       "label": "Jan 9, 2018",
       "cells": [
        "PANGIA ROBERT W Director",
        "Sell",
        "5.8K",
        "$1.9M"
       ]
      },
      {
       "label": "Nov 14, 2022",
       "cells": [
        "GREGORY GINGER Officer",
        "Sell",
        "5.6K",
        "$1.7M"
       ]
      },
      {
       "label": "Oct 27, 2022",
       "cells": [
        "ALEXANDER SUSAN H Officer",
        "Sell",
        "5.5K",
        "$1.6M"
       ]
      },
      {
       "label": "Jul 25, 2017",
       "cells": [
        "ALEXANDER SUSAN H Officer",
        "Sell",
        "5.0K",
        "$1.4M"
       ]
      },
      {
       "label": "Jun 7, 2021",
       "cells": [
        "GUINDO CHIRFI Officer",
        "Sell",
        "3.1K",
        "$1.4M"
       ]
      },
      {
       "label": "Mar 7, 2025",
       "cells": [
        "SHERWIN STEPHEN A Director",
        "Sell",
        "8.8K",
        "$1.3M"
       ]
      },
      {
       "label": "Apr 28, 2023",
       "cells": [
        "GREGORY GINGER Officer",
        "Sell",
        "2.7K",
        "$804.3K"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=Biogen+Inc.&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "What is Biogen Inc.'s current consensus rating?",
   "answer": "Biogen Inc. currently holds a 'Buy' consensus rating from Wall Street analysts. This rating is supported by a consensus score of 68 out of 100, reflecting a generally positive outlook from the investment community."
  },
  {
   "question": "What is the median analyst price target for Biogen Inc. stock?",
   "answer": "The median analyst price target for Biogen Inc. is $240.00, which suggests an upside potential of 10.5% from its current trading price of $217.10."
  },
  {
   "question": "How has Biogen Inc. performed in recent earnings reports?",
   "answer": "Biogen Inc. has consistently beaten earnings per share estimates in recent quarters, including a significant 77.34% surprise in its latest report. This indicates strong operational performance, though recent price action has not always reflected these beats."
  },
  {
   "question": "What are the key technical indicators for Biogen Inc.?",
   "answer": "Biogen Inc. is trading above its 50-day and 200-day moving averages ($209.47 and $191.92), indicating a bullish trend. However, its RSI is neutral at 50.41, suggesting a lack of strong momentum in either direction."
  },
  {
   "question": "What is the revenue growth outlook for Biogen Inc.?",
   "answer": "Analyst estimates project revenue growth of approximately 4.00% for the current quarter and 6.00% for the full year. This indicates steady, albeit moderate, top-line expansion for the company."
  },
  {
   "question": "Are there any significant insider transactions for Biogen Inc.?",
   "answer": "Insider activity for Biogen Inc. indicates a 'Moderate Sell Signal,' with total sales amounting to $1.8 million compared to $152.1 thousand in purchases. This suggests a net seller stance among insiders."
  },
  {
   "question": "How does Biogen Inc. compare to its sector averages?",
   "answer": "Biogen Inc.'s P/E ratio of 37.47 is slightly higher than the healthcare sector's median P/E of 31.9. However, its revenue growth of 3.4% is below the sector median of 8.1%, while its ROE is not directly comparable without further data but the sector median is 6.9%."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "NEOG",
    "name": "Neogen Corp. NASDAQ",
    "price": "$11.78",
    "change": "+0.08%",
    "url": "https://clearank.com/stock/neogen-neog/"
   },
   {
    "ticker": "MOH",
    "name": "Molina Healthcare Inc. NYSE",
    "price": "$204.23",
    "change": "+1.97%",
    "url": "https://clearank.com/stock/moh-stock-analysis/"
   },
   {
    "ticker": "VKTX",
    "name": "Viking Therapeutics, Inc. NASDAQ",
    "price": "$31.98",
    "change": "-0.47%",
    "url": "https://clearank.com/stock/viking-therapeutics-vktx/"
   },
   {
    "ticker": "BMY",
    "name": "Bristol-Myers Squibb Company NYSE",
    "price": "$63.64",
    "change": "-0.17%",
    "url": "https://clearank.com/stock/bristol-myers-squibb-bmy/"
   },
   {
    "ticker": "VEEV",
    "name": "Veeva Systems Inc. NYSE",
    "price": "$262.25",
    "change": "+0.49%",
    "url": "https://clearank.com/stock/veev-stock-analysis/"
   },
   {
    "ticker": "TLRY",
    "name": "Tilray Brands Inc. NASDAQ",
    "price": "$4.02",
    "change": "-2.90%",
    "url": "https://clearank.com/stock/tilray-brands-tlry/"
   },
   {
    "ticker": "CRNX",
    "name": "Crinetics Pharmaceuticals, Inc. NASDAQ",
    "price": "$84.95",
    "change": "+0.00%",
    "url": "https://clearank.com/stock/crinetics-pharmaceuticals-crnx/"
   },
   {
    "ticker": "CNC",
    "name": "Centene Corp. NYSE",
    "price": "$66.42",
    "change": "+1.56%",
    "url": "https://clearank.com/stock/centene-cnc/"
   }
  ],
  "comparisons": [
   {
    "ticker": "SLV vs SIVR Comparison",
    "name": "",
    "url": "https://clearank.com/compare/slv-vs-sivr/"
   },
   {
    "ticker": "TSLA vs NVDA Comparison",
    "name": "",
    "url": "https://clearank.com/compare/tsla-vs-nvda/"
   },
   {
    "ticker": "VGT vs QQQM Comparison",
    "name": "",
    "url": "https://clearank.com/compare/vgt-vs-qqqm/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "SLVR",
    "text": "Sprott Silver Miners & Physical Silver ETF",
    "url": "https://clearank.com/etf/slvr-etf-analysis/"
   },
   {
    "ticker": "NTES",
    "text": "NetEase, Inc.",
    "url": "https://clearank.com/stock/ntes-stock-analysis/"
   },
   {
    "ticker": "PCAR",
    "text": "PACCAR Inc.",
    "url": "https://clearank.com/stock/pcar-stock-analysis/"
   },
   {
    "ticker": "O",
    "text": "Realty Income Corp.",
    "url": "https://clearank.com/stock/o-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "ASPI",
    "text": "↓ 7.80%",
    "url": "https://clearank.com/stock/aspi-asp-isotopes/"
   },
   {
    "ticker": "SMR",
    "text": "↓ 15.67%",
    "url": "https://clearank.com/stock/nuscale-power-smr/"
   },
   {
    "ticker": "XHLD",
    "text": "↑ 15.04%",
    "url": "https://clearank.com/stock/xhld-stock-analysis/"
   },
   {
    "ticker": "HPE",
    "text": "↑ 12.44%",
    "url": "https://clearank.com/stock/hewlett-packard-enterprise-hpe/"
   },
   {
    "ticker": "DELL",
    "text": "↑ 11.98%",
    "url": "https://clearank.com/stock/dell-technologies-dell/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "ABBV",
    "text": "AbbVie",
    "url": "https://clearank.com/stock/abbvie-abbv/"
   },
   {
    "ticker": "AMGN",
    "text": "Amgen",
    "url": "https://clearank.com/stock/amgen-amgn/"
   },
   {
    "ticker": "BMY",
    "text": "Bristol-Myers Squibb",
    "url": "https://clearank.com/stock/bristol-myers-squibb-bmy/"
   },
   {
    "ticker": "GILD",
    "text": "Gilead Sciences",
    "url": "https://clearank.com/stock/gilead-sciences-gild/"
   },
   {
    "ticker": "JNJ",
    "text": "Johnson & Johnson",
    "url": "https://clearank.com/stock/johnson-johnson-jnj/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "url": "https://clearank.com",
     "sameAs": [
      "https://twitter.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank"
     ],
     "email": "info@clearank.com",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "description": "The CleaRank vision is to bring clarity to the online trading industry and protect trader interests. We use our proprietary technology, expert analysis and verified trader insights, to deliver data driven broker evaluations you can trust. Our CLEAR™ Score is our foundation, a transparent, unbiased methodology that assesses brokers and firms based on the most critical factors including regulation, fees, platform reliability, and real user experiences. We are here to change an unfair system and unlike other review sites that are influenced by partnerships or subjective opinions, CleaRank is 100% independent–abiding by our rigorous CLEAR™ editorial code. We do not accept financial incentives from brokers, so what you see is what you get with no hidden agendas, just honest, actionable feedback. Clear data. Honest reviews. That's the CleaRank promise",
     "numberOfEmployees": {
      "@type": "QuantitativeValue",
      "value": "40"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/06/comparison-og-default.png",
     "url": "https://clearank.com/wp-content/uploads/2026/06/comparison-og-default.png",
     "width": "1200",
     "height": "630",
     "caption": "CleaRank head-to-head comparison",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/biib-stock-analysis/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/biib-stock-analysis/",
        "name": "Biogen Inc. (BIIB) Stock Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/biib-stock-analysis/#webpage",
     "url": "https://clearank.com/stock/biib-stock-analysis/",
     "name": "Biogen Inc. (BIIB) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-08-20T06:31:53+00:00",
     "dateModified": "2026-09-11T22:03:17+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/06/comparison-og-default.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/biib-stock-analysis/#breadcrumb"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/writer/clearank/",
     "name": "CleaRank",
     "description": "CleaRank's vision is to bring clarity to the online trading industry and protecting trader interests by delivering data-driven broker evaluations you can trust.",
     "url": "https://clearank.com/writer/clearank/",
     "image": {
      "@type": "ImageObject",
      "@id": "https://secure.gravatar.com/avatar/4900cf75f960a22a21f1c864e98abc4d5285fa159ea1025d0e8a9db5136e28ef?s=96&d=mm&r=g",
      "url": "https://secure.gravatar.com/avatar/4900cf75f960a22a21f1c864e98abc4d5285fa159ea1025d0e8a9db5136e28ef?s=96&d=mm&r=g",
      "caption": "CleaRank",
      "inLanguage": "en-US"
     },
     "sameAs": [
      "https://clearank.com/",
      "https://twitter.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     },
     "logo": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg"
    },
    {
     "@type": "Article",
     "headline": "Biogen Inc. (BIIB) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-08-20T06:31:53+00:00",
     "dateModified": "2026-09-11T22:03:17+00:00",
     "author": {
      "@id": "https://clearank.com/writer/clearank/",
      "name": "CleaRank"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "description": "Biogen Inc. (BIIB) stock: Healthcare, Drug Manufacturers - General. $32.1B market cap. AI rating, technicals, 2030 forecast and trade plans.",
     "name": "Biogen Inc. (BIIB) Stock Forecast & Price Target (2026)",
     "@id": "https://clearank.com/stock/biib-stock-analysis/#richSnippet",
     "isPartOf": {
      "@id": "https://clearank.com/stock/biib-stock-analysis/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/06/comparison-og-default.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/biib-stock-analysis/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FinancialProduct",
   "name": "Biogen Inc. (BIIB)",
   "tickerSymbol": "BIIB",
   "url": "https://clearank.com/stock/biib-stock-analysis/",
   "description": "AI-powered financial analysis for Biogen Inc. (BIIB) including technical indicators, market metrics, valuation, and price targets - refreshed daily by CleaRank Financial AI.",
   "exchange": "NASDAQ",
   "offers": {
    "@type": "Offer",
    "price": 217.10001,
    "priceCurrency": "USD",
    "availability": "https://schema.org/InStock",
    "url": "https://clearank.com/stock/biib-stock-analysis/",
    "priceValidUntil": "2026-09-13"
   }
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "What is Biogen Inc.'s current consensus rating?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Biogen Inc. currently holds a 'Buy' consensus rating from Wall Street analysts. This rating is supported by a consensus score of 68 out of 100, reflecting a generally positive outlook from the investment community."
     }
    },
    {
     "@type": "Question",
     "name": "What is the median analyst price target for Biogen Inc. stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The median analyst price target for Biogen Inc. is $240.00, which suggests an upside potential of 10.5% from its current trading price of $217.10."
     }
    },
    {
     "@type": "Question",
     "name": "How has Biogen Inc. performed in recent earnings reports?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Biogen Inc. has consistently beaten earnings per share estimates in recent quarters, including a significant 77.34% surprise in its latest report. This indicates strong operational performance, though recent price action has not always reflected these beats."
     }
    },
    {
     "@type": "Question",
     "name": "What are the key technical indicators for Biogen Inc.?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Biogen Inc. is trading above its 50-day and 200-day moving averages, indicating a bullish trend. However, its RSI is neutral at 50.41, suggesting a lack of strong momentum in either direction."
     }
    },
    {
     "@type": "Question",
     "name": "What is the revenue growth outlook for Biogen Inc.?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Analyst estimates project revenue growth of approximately 4.00% for the current quarter and 6.00% for the full year. This indicates steady, albeit moderate, top-line expansion for the company."
     }
    },
    {
     "@type": "Question",
     "name": "Are there any significant insider transactions for Biogen Inc.?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Insider activity for Biogen Inc. indicates a 'Moderate Sell Signal,' with total sales amounting to $1.8 million compared to $152.1 thousand in purchases. This suggests a net seller stance among insiders."
     }
    },
    {
     "@type": "Question",
     "name": "How does Biogen Inc. compare to its sector averages?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Biogen Inc.'s P/E ratio of 37.47 is slightly higher than the healthcare sector's median P/E of 31.9. However, its revenue growth of 3.4% is below the sector median of 8.1%, while its ROE is not directly comparable without further data but the sector median is 6.9%."
     }
    }
   ]
  }
 ]
}